A Three-part Open-label, Non-randomised, Dose-escalation Study to Investigate the Safety and Tolerability of GSK3039294 Administered as a Single Dose to Healthy Volunteers, and as Repeat Dose to Healthy Volunteers and Patients With Systemic Amyloidosis
Phase of Trial: Phase I
Latest Information Update: 27 Apr 2017
At a glance
- Drugs GSK 3039294 (Primary)
- Indications Amyloidosis
- Focus Adverse reactions
- Sponsors GlaxoSmithKline
- 24 Apr 2017 Planned End Date changed from 11 Sep 2017 to 17 Oct 2017.
- 24 Apr 2017 Planned primary completion date changed from 11 Sep 2017 to 17 Oct 2017.
- 06 Apr 2017 Planned primary completion date changed from 1 Jul 2017 to 11 Sep 2017.